Table 2.

Results of Regression Analysis of Cumulative Burden by Demographic and Treatment Exposures

	Model 1*: Overall Rate		Model 2*: Propensity for a Higher Grade Condition
			Grade 2 vs. 1		Grade 3–5 vs. 1
	RR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value
Gender
Male	-	-	Ref		Ref
Female	-	-	1·26 (1·18 – 1·35)	<0·001	1·31 (1·22 – 1·41)	<0·001
Race
White	-	-	Ref		Ref
Other	-	-	1·00 (0·92 – 1·09)	0·93	1·15 (1·05 – 1·27)	0·003
Age at Diagnosis
0–4	Ref		Ref		Ref
5–9	0·71 (0·66 – 0·76)	<0·001	1·04 (0·95 – 1·13)	0·39	1·12 (1·01 – 1·24)	0·029
10–14	0·46 (0·43 – 0·50)	<0·001	1·06 (0·93 – 1·19)	0·38	1·26 (1·10 – 1·44)	<0·001
15+	0·33 (0·30 – 0·35)	<0·001	1·06 (0·90 – 1·26)	0·47	1·51 (1·28 – 1·78)	<0·001
Year of Diagnosis
<1980	0·48 (0·44 – 0·51)	<0·001	1·21 (1·08 – 1·35)	0·001	1·57 (1·36 – 1·80)	<0·001
1980–1994	Ref		Ref		Ref
1995 or Later	2·54 (2·37 – 2·72)	<0·001	0·94 (0·82 – 1·07)	0·34	0·59 (0·51 – 0·68)	<0·001
Anthracycline Dose
None	Ref		Ref		Ref
1–249 mg/m2	1·18 (1·10 – 1·27)	<0·001	0·89 (0·81 – 0·98)	0·015	0·78 (0·71 – 0·85)	<0·001
≥250 mg/m2	1·22 (1·12 – 1·33)	<0·001	0·94 (0·84 – 1·05)	0·28	0·95 (0·85 – 1·07)	0·40
Methotrexate
No	Ref		-	-	-	-
Yes	0·83 (0·75 – 0·91)	<0·001	-	-	-	-
CED Dose**
None	-	-	Ref		Ref
1–6,300 mg/m2	-	-	1·04 (0·94 – 1·14)	0·48	1·04 (0·94 – 1·16)	0·42
6,301–10,893 mg/m2	-	-	0·98 (0·89 – 1·08)	0·62	0·99 (0·90 – 1·09)	0·86
≥10 ,893 mg/m2	-	-	1·10 (0·99 – 1·21)	0·06	1·12 (1·01 – 1·25)	0·023
Bleomycin
No	-	-	Ref		Ref
Yes	-	-	1·20 (1·04 – 1·38)	0·010	1·25 (1·06 – 1·47)	0·006
Cytarabine
No	Ref		-	-	-	-
Yes	1·23 (1·13 – 1·34)	<0·001	-	-	-	-
Plant Alkaloids
No	Ref		-	-	-	-
Yes	0·88 (0·82 – 0·96)	0·001	-	-	-	-
Platinum Agents
No	Ref		Ref		Ref
Yes	1·29 (1·16 – 1·43)	<0·001	1·12 (0·98 – 1·29)	0·09	1·07 (0·92 – 1·23)	0·38
Steroids
No	Ref		Ref		Ref
Yes	1·13 (1·02 – 1·26)	0·016	0·97 (0·87 – 1·07)	0·50	0·92 (0·84 – 1·01)	0·08
Brain Radiation Dose***
None	Ref		Ref		Ref
<18Gy	1·08 (0·97 – 1·20)	0·17	1·12 (0·95 – 1·31)	0·16	1·07 (0·92 – 1·24)	0·37
18–<30Gy	1·04 (0·97 – 1·12)	0·28	1·11 (1·00 – 1·24)	0·05	1·14 (1·03 – 1·28)	0·014
30–<40Gy	1·19 (0·93 – 1·52)	0·15	1·09 (0·76 – 1·56)	0·63	1·10 (0·78 – 1·55)	0·56
40+Gy	1·57 (1·43 – 1·72)	<0·001	1·27 (1·09 – 1·46)	0·001	1·24 (1·09 – 1·42)	0·001
Chest Radiation Dose***
None	Ref		Ref		Ref
<10Gy	0·95 (0·87 – 1·05)	0·33	1·20 (1·03 – 1·40)	0·015	1·08 (0·92 – 1·28)	0·34
10+Gy	1·41 (1·32 – 1·50)	<0·001	1·31 (1·18 – 1·46)	<0·001	1·14 (1·01 – 1·28)	0·030
Pelvic Radiation
No	-	-	Ref		Ref
Yes	-	-	1·12 (1·01 – 1·24)	0·029	1·05 (0·94 – 1·18)	0·35

^*For both models, backward selection was conducted from a set of exposure variables.

^**CED Dose: Cyclophosphamide equivalent dose with category cutoffs based on tertiles.

^***Assigned dose is the maximum dose received within the region.